Putting progress into practice for HCV care in Egypt
|
|
- Megan Nelson
- 8 years ago
- Views:
Transcription
1 Putting progress into practice for HCV care in Egypt Chairs: Maria Buti, Ashraf Abou-Gabal, Sami Abdel Fattah, Ali Farag, Faisal Sanai This session has been funded by Gilead Sciences Europe The content of the programme is at the discretion of the faculty
2 Session disclaimer This is an independent programme for which Gilead Sciences Europe Ltd. ( Gilead ) provided funding; Gilead has had no input into the content of the materials and/or presentations used during this session This session includes reference to use of unlicensed products or unlicensed indications The presentations express the views and opinions of the presenter which were based on information and data available at the time Any patient cases and treatment options referred to are in the context of contemporary knowledge and medical practice in the field; unlicensed doses and indications are included
3 Hepatology on the Nile 2 Putting Progress into Practice for HCV Care in Egypt Cairo, 25 September 2014 Welcome Maria Buti Autónoma University, Barcelona; Chief of Internal Medicine and Hepatology, Vall d Hebron University Hospital, Barcelona, Spain
4 Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis Lecturer: Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis Clinical trials: Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis, Roche
5 Programme and faculty revised Time Title Speaker Welcome & introduction Maria Buti (Spain) HCV co-infection: no longer a special population? Karine Lacombe (France) HCV guidelines: from paper to practice Ashley Brown (UK) Can we take HCV out of the transplant equation? Linking care to cure in difficult-to-reach populations Maria Buti (Spain) Ashley Brown (UK) Summary Maria Buti (Spain) Close
6 Global HCV burden and genotype distribution 6 HCV genotypes (GT 1 6) GT 1 and GT 4 predominate in Egypt and Middle East Messina JP, et al. Hepatol 2014; doi: /hep GT: genotype
7 HCV a uniquely Egyptian epidemic Egypt s HCV burden is at least 4 x greater than that of any other country 1 in 7 sero-positive (global average 1 in 50) But, not only is the Egyptian HCV problem one of size, the prevalent GT 4 is one that is not commonly found in the rest of the world Drug development has primarily focused on GT 1 to date Yahia M, Nature 2011:474:S12 3
8 The unique Egyptian situation requires a unique approach to HCV management Number of individuals with late-stage liver disease is projected to increase 1 Although Egypt now has the world s largest HCV treatment programme, 2 the current treatment rate and efficacy are not sufficient to manage the disease burden 1 The National Treatment Programme needs to evolve with the availability of new drugs 1. Razavi H, et al. J Viral Hepatitis 2014;21(Suppl 1):34 59; 2. Waked I et al. Arab J Gastro. 2014;15:45 52.
9 Benefits of second wave anti-hcv DAAs SVR rates 90% Pangenotypic, short treatment courses Better adverse effect profiles
10 Hepatology on the Nile 2 Putting Progress into Practice for HCV Care in Egypt Cairo, 25 September 2014 Can we take HCV out of the transplant equation? Maria Buti Autónoma University, Barcelona; Chief of Internal Medicine and Hepatology, Vall d Hebron University Hospital, Barcelona, Spain
11 Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis Lecturer: Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis Clinical trials: Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Novartis, Roche Note: This presentation includes reference to investigational agents not currently approved for use in HBV by the EMA, FDA and Egyptian MOH
12 Most liver transplants (LT) in Europe due to cirrhosis are caused by hepatitis viruses European analysis of 55,714 transplants in Europe 1 2% 1% 8% 4% 4% 9% 39% Virus-related Alcoholic Viral and alcoholic Autoimmune Secondary biliary Unknown 33% Primary biliary Others HCV-related cirrhosis accounts for 66% of virus-related LT, therefore approximately 25% of LT are a result of HCV 2 1. European liver transplant registry LTR. ww.eltr.org/spip.php?article162 (accessed September 2014); 2. EASL. The burden of liver disease in Europe. (accessed June 2014) Study period January 1998 December 2012
13 This is also true in Egypt Egyptian analysis of 58 transplant candidates (12 transplanted; 46 control) 48% 43% Virus-related Biliary Schistosomiasis Cryptogenic Mixed 2% 3% 3% Khalaf H, et al. Suez Canal Univ Med J. 2000:3;157 67
14 Challenges for liver transplantation in Egypt Cadaveric organ donation is illegal in Egypt Many patients travel to America, Europe or China Living donor liver transplantation (LDLT) has provided the only option for patients with ESLD Donor must be the patient s relative, between years old and free of any diseases Concerns over organ donation for money In Western countries, the average waiting time for an overseas patient to receive a cadaveric graft is months Significant mortality during this waiting period 1. Yosry A, et al. Transplantation Proceedings. 2008:40;1481 4; 2. El-Gazzaz GH and El-Elemi AH, Transplant Research and Risk Management. 2010:2;41 46 ESLD: end-stage liver disease
15 Decreased survival among HCV-infected liver transplanted recipients: Patient survival (%) P= log-rank test HCV- HCV+ Years HCV+ HCV- 1 77% 87% % 83% % 76% % 70% Years post-transplantation Berenguer et al, Hepatology 2002;36:
16 Reduced liver-related mortality liver graft recipients with recurrent HCV who achieve SVR Probability of survival in patients who did not maintain SVR (n=61) 1 Patient survival since treatment initiation in patients without baseline cirrhosis (n=78) Sustained virological responders 1.0 Survival Probability (%) Patients with treatment failure Patient survival (%) SVR Yes No Yes-censored No-censored Months Follow-up since treatment initiation (days) 1. Picciotto et al, J. Hepatology 2007; 2. Berenguer, Am. J. of Transplant SVR: sustained virologic response; TF: treatment failure
17 Recurrent HCV treatment with TVR or BOC + PEG- IFN/RBV: Cohort and clinical studies Authors DAA Pts Population GT 1a SVR12 Discontinuation Faisal et al TVR 76 F0-F2 72% 58% 44% BOC Burton et al TVR 125 F3-F4 48% 58% 59% 20% Coilly et al TVR 79 F3-F4, FCH 78% BOC 33% 46% 55% Pungpapong et al TVR 60 F3-F4 50% FCH 8% 68% 50% 20% Predictors : SVR: Ciclosporin, Treatment duration, Infections: FCH, Bilirubin; Anaemia, Thrombocytopenia Faisal et al, Ann of Hepatol 2014;13:525-32; Burton et al, J Hepatol Sep;61:508-14; Coilly et al, J Hepatol 2014;60:78-86; Pungpapong et al, Liver Transpl 2013;19: BOC: boceprevir; ; DAA: direct-acting antiviral FCH: fibrosing cholestatic hepatitis; GT: genotype; PEG-IFN: pegylated interferon; Pts: patients; RBV: ribavirin; TVR: telaprevir
18 Clinical case 1 Male patient, 52 years old, GT 4 Liver transplant in 2008 Recurrence of HCV FCH; FibroScan = 18.9 kpa; MELD = 26 Bilirubin: 13 mg/dl (223 µmol/l); albumin: 35 g/l (3.5 g/dl) Treated with PEG-IFN + RBV Failed to respond What are his next options? FCH: fibrosing cholestatic hepatitis; MELD: model for end-stage liver disease
19 EASL: Recommended treatment options: Indication for LT Child-Pugh A with HCC: SOF + RBV until LT SOF + daclatasvir + RBV until LT probably better Finite (12 weeks) SOF + PEG-IFN + RBV also acceptable Patients with decompensated cirrhosis awaiting LT (Child-Pugh B or C) SOF + RBV in experienced centres under close monitoring SOF + daclatasvir + RBV until LT probably better Patients with post-transplant recurrence of HCV infection should be considered for therapy IFN-free treatment is recommended No dose-adjustment is required for tacrolimus or ciclosporin with any of the available combinations EASL Recommendations on Treatment of Hepatitis C Accessed September 2014 HCC: hepatocellular carcinoma; IFN: interferon; SOF: sofosbuvir
20 Safety and tolerability profiles of newly approved DAAs: Simeprevir and sofosbuvir Simeprevir (2nd wave PI) 1 Once-daily dosing GT 1, 4 Main AEs Rash including (22%) Pruritus (22%) Photosensitivity (5%) Mild hyperbilirubinaemia (27%) Due to OATP1B1/MRP2 transporter inhibition Resistance in treatment failures Sofosbuvir 2 Once daily dosing Pangenotypic Minimal AEs Headache ~20% No resistance detected in treatment failures 1. Janssen. OLYSIO (simeprevir). Summary of Product Characteristics, May 2014; 2. Gilead Sciences Europe. SOVALDI (sofosbuvir), Summary of Product Characteristics, January 2014 AE: adverse event; DAA: direct acting antiviral; OATP: organic anion-transporting peptide; MRP: multidrug resistant protein
21 SOF + RBV for established recurrent HCV post-lt LT 6 months and 150 months MELD 17 Treatment-naïve and treatment-experienced with recurrent HCV (N=40) SOF 400 mg/d + RBV starting at 400 mg/d with dose escalation SVR12 Study week No response guided therapy SOF + RBV (N=40) Male, n (%) 31 (78) Median age, y (range) 59 (49 75) Genotype, %: 1a / 1b / 2 /3 / 4 55/28/0/15/3 Metavir-equivalent fibrosis stage, % F0 F2/F3/F4 38/23/40 Prior HCV treatment, % Previous PI failures, % Immunosuppressants (%): tacrolimus/ mycophenolate mofetil/ prednisone/ciclosporin/azathioprine /35/ 28/25/5 63% F3/4 Samuel D, et al. EASL 2014; Poster #1232
22 SOF + RBV for 24 weeks resulted in high SVR rates HCV RNA <LLOQ (%) /40 40/40 29/40 28/40 28/40 Week 4 EOT SVR4 SVR12 SVR24 Relapse was not influenced by RBV dose or exposure No DDI between SOF and any immunosuppressive agents in this study SOF + RBV in patients with recurrent HCV after LT was well tolerated No deaths, graft losses or episodes of rejection reported Samuel D, et al. EASL 2014; Poster #1232 DDI: drug drug interactions; EOT: end of therapy; LLOQ, lower limit of quantification (25 IU/mL)
23 Compassionate use of SOF in patients with severe recurrent HCV Including FCH following LT Severe recurrent hepatitis C post-lt likely to have <1 yr life expectancy SOF 400 mg/d for weeks plus RBV ± PEG-IFN Severe acute hepatitis/early recurrence (<12 mo from LT with typical biochemical-histological findings), n=48 Post-LT compensated (F4) or decompensated cirrhosis, n=56 Early term due to AE n=7 Liver transplant n=12 Death n=13 SOF Compassionate Use Programme SOF + RBV ± PEG, n=104 Completed weeks treatment n=72 Forns X. EASL, London 2014
24 Results: Baseline characteristics Overall (n=104) Age, years 55 (16 76) Male recipient 76 (73%) HCV RNA, log 10 IU/mL 8.4 ( ) GT, 1 / 4 vs 2 / 3 88 / 8 vs 1 / 7 Bilirubin, mg/dl 3.1 (0.4 45) Albumin, g/dl 3.1 ( ) INR 1.3 ( ) ALT, IU/L 71 (8 1162) MELD 15 (6 43) Time from LT to treatment, months 17 (1 262) Forns X. EASL, London 2014
25 Overall, 62% of patients achieved SVR 100 4/93 Patients (%) /93 15/85 4/85 13/85 HCV RNA >LLOQ Lost to follow up Death HCV RNA <LLOQ 62% SVR /93 53/85 EOT SVR12 Forns X. EASL, London 2014
26 Over 79% of patients receiving at least 1 dose of SOF improved or were stable All patients who received 1 dose of SOF are included % improved or stable Patients (%) /104 22/104 22/104 Improved* Stable Worsened/deceased * Significant decrease in hepatic encephalopathy, improvement or disappearance of ascites, or improvement in liver-related laboratory values Forns X. EASL, London 2014
27 Post-transplant recurrent hepatitis C Patients with post-transplant recurrence of HCV infection should be considered for therapy IFN-free treatment is recommended No dose adjustment is required for tacrolimus or ciclosporin with the available combinations
28 Clinical case 2 Male patient, 52 years old, GT 4 cirrhotic HCV infection since 2001 Treated with PEG-IFN + RBV Could not tolerate the full dose and only achieved a partial response Platelet count: 60 x 10 3 /µl; albumin: 3.2 g/dl (32 g/l); bilirubin: 4.5 mg/dl (77 µmol/l), mild ascites; MELD=15 HCC diagnosed in November 2013 and on LT waiting list What could be done before a donor liver becomes available? HCC: hepatocellular carcinoma; MELD: model of end-stage liver disease
29 SOF + RBV pre-lt to prevent HCV recurrence post-lt Open-label, Phase 2, GT 1 6 study of SOF + RBV for the prevention of recurrent HCV infection Undergoing LT for HCC 2 to HCV N=61 Time 0 SOF 400 mg/day + RBV mg/day No response guided therapy Liver transplant (up to 48 weeks) 12 weeks post-transplant virological response (ptvr) SOF + RBV (N=61) Male, n (%) 49 (80) Median age, y (range) 59 (46 73) BMI < 30 kg/m 2, n (%) 43 (70) Genotype, % 1a/1b/2/3a/4 39/34/13/11/2 IL28B non-cc allele, n (%) 47/60 (78) CPT score, n (%) 5/6/7/8 43/30/23/5 Median MELD score, (range) 8 (6 14) Prior HCV treatment, n (%) 46 (75) Curry MP, et al. ILTS 2014; Oral #137 SOF: sofosbuvir; 2 o :secondary
30 SOF + RBV suppressed viral load and prevented HCV recurrence post-transplant Post-transplant virological response >30 days TND No Recurrence (n=30) Recurrence (n=10) Viral response rate (%) Transplant 70 43/46* 30/43* ptvr12 No recurrence in 24/25 (96%) of patients who maintained HCV RNA TND >30 days Median days TND No recurrence: 99 Recurrence: 5.5 p <0.001 Of the 61 patients treated, 46 underwent LT Days with HCV RNA Continuously TND Prior to Liver Transplant SOF + RBV treatment prior to transplantation prevented HCV recurrence in most patients (70%) who were HCV RNA <LLOQ (TND) at time of LT Curry MP, et al. ILTS 2014; Oral #137 *3 subjects were >LLOQ at transplant; 1 subject has not reached ptvr12; BL: baseline; SD: standard deviation; TND: target not detected
31 HCV care is progressing and this will also be the case for LT patients Several IFN-free regimens are at an advanced stage of development, including: SOF + daclatasvir Ledipasvir/SOF Paritaprevir/ritonavir/ombitasvir + dasabuvir ± RBV MK-5172/MK-8742 ± RBV Asunaprevir, ledipasvir, paritaprevir/ritonavir, ombitasvir, dasabuvir, MK-5172 and MK-8742 are investigational agents and not approved for use in HCV by the EMA, FDA or Egyptian MOH
32 Paritaprevir/ritonavir/ombitasvir + dasabuvir + RBV in LT recipients with recurrent GT 1 24 weeks therapy in LT recipients with recurrent GT 1 infection; treatment-naïve; F0 2 (n=34); CNI doses adjusted for paritaprevir/r % HCV RNA undetectable /34 34/34 32/33 25/26 Week 4 (RVR) Week 24 (EOT) SVR4 SVR12 There were no on-treatment failures One patient experienced relapse (post-treatment Day 3) Clinically relevant DDIs seen between regimen and immunosuppressants Kwo P. EASL 2014; oral #114 Paritaprevir/ritonavir, ombitasvir and dasabuvir are investigational agents and not approved for use in HCV by the EMA, FDA or Egyptian MOH CNI: calcineurin inhibitor; EOT: end of therapy; RVR: rapid virological response
33 Ongoing clinical trials including HCV transplant recipients Identifier Regimen Treatment Duration Genotype Child Pugh class Trial Phase NCT LDV/SOF + RBV wk 1, 4 Pre-LT: B, C Post-LT: A, B, C 2 NCT DCV/SOF + RBV 12 wk 1 6 Pre- and Post-LT: A 3 NCT DCV + SMV + RBV 24 wk 1b Post LT Metavir F1 F4 (Child A) 2 NCT Paritaprevir/r/ Ombitasvir + Dasabuvir ± RBV 12 wk 1 Post LT Metavir F1 F3 (no cirrhotics allowed) 2 Forns et al, Digestive and Liver Disease in press; Paritaprevir/ritonavir, ombitasvir and dasabuvir are investigational gents and not approved for use in HCV by the EMA, FDA or Egyptian MOH; DCV: daclatasvir; LDV: ledipasvir; r: ritonavir; Wk: week
34 Drug drug interactions between DAAs and calcineurin inhibitors DAA Ciclosporin Tacrolimus Healthy volunteers Dose adjustment Healthy volunteers Dose adjustment Boceprevir 1,2 * AUC 2.7 fold 2 fold AUC 17 fold 5 fold Telaprevir 2,3 ** AUC 4.6 fold 4 fold AUC 70 fold 35 fold Paritaprevir/r 4 AUC 5.8 fold 5 fold AUC 58 fold 100 fold Simeprevir 5 AUC 19% Under investigation. Not recommended AUC 17% Not necessary Sofosbuvir 6 No change Not necessary No change Not necessary Daclatasvir 7 No change Not necessary No change Not necessary *AUC Inf is given **AUC Last is given Adapted from Forns et al, Digestive and Liver Disease in press Paritaprevir is not approved for use in HCV by EMA, FDA or Egyptian MOH 1.Hulskotte et al. Hepatology 2012;56: Coilly et al. Antimicrob Agents Chemother 2012;56: Coilly et al. Liver Int 2013;33 Suppl 1: Kwo P et al. J Hepatol 2014;60(Suppl 1):S47. 5.Ouwerkerk-Mahadevan et al. J Hepatol 2013;58(S1):S Mathias et al. Hepatology 2012;56(Suppl 1): 1063A-1064A. 7.Fontana et al. Liver Transpl 2012;18:
35 Summary taking HCV out of the transplant equation The future is more optimistic for patients with HCV-related ESLD Clear evidence that re-infection post-lt can be prevented by treating HCV before the procedure and cured afterwards with effective DAA treatment, even in those with the severest form of disease SOF + RBV data show promise high efficacy and no DDIs with common immunosuppressant agents To put progress into practice in Egypt, a transformation in management approach is required so that patients are cured of HCV before they require a transplant
36 Q&A
37 Hepatology on the Nile 2 Putting Progress into Practice for HCV Care in Egypt Cairo, 25 September 2014 Meeting Close Maria Buti Autónoma University, Barcelona; Chief of Internal Medicine and Hepatology, Vall d Hebron University Hospital, Barcelona, Spain
38 Vision for future treatment of chronic HCV: Putting progress into practice ALL PATIENTS ALL HCV GTs 1 6 including BOC/TVR failures including decompensated cirrhosis Including HIV/HCV co-infection 1 Pill/day for 8 12 wks Simple prescribing Treatment uptake Health burden
39 Putting progress into practice for HCV care in Egypt: Summary Recent advances, once accessible, have the potential to transform and simplify patient management New potent, pangenotypic, well tolerated IFN-limiting and IFN-free treatment options of short duration are emerging Need to prioritise and treat now those patients with greatest need Need to preventing the currently high rates of reinfection through appropriate hygiene manoeuvers
40 THANK YOU FOR YOUR ATTENTION
41 Putting progress into practice for HCV care in Egypt Chairs: Maria Buti, Ashraf Abou-Gabal, Sami Abdel Fattah, Ali Farag, Faisal Sanai This session has been funded by Gilead Sciences Europe The content of the programme is at the discretion of the faculty
Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationTreatment of Hepatitis C in Patients with Renal Insufficiency
HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred
More informationEASL Recommendations on Treatment of Hepatitis C 2015 SUMMARY
JULY 2015 EASL Recommendations on Treatment of Hepatitis C 2015 Contents SUMMARY 1. Diagnosis of acute and chronic hepatitis C 2. Screening for chronic hepatitis C 3. Goals and endpoints of HCV therapy
More informationTreatment of Chronic Hepatitis C - September 2014 Update
Treatment of Chronic Hepatitis C - September 014 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Darius Moradpour, Andri Rauch, Jan Fehr and Beat
More informationHepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationFocus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationLedipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationI. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health Contents I. What
More informationGUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF
NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationRecurrent HCV Following Liver Transplantation
Recurrent HCV Following Liver Transplantation Russell H. Wiesner, MD Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA ILTS Western/Eastern Perspective Hong Kong, CHINA April 5-6,
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Q1-2013 Conference Call - Presenting team Maris Hartmanis, CEO Charlotte
More informationManagement of Chronic HCV Cirrhosis: Pre and Post-Liver Transplantation
Management of Chronic HCV Cirrhosis: Pre and Post-Liver Transplantation K.Rajender Reddy M.D., Professor of Medicine and Surgery Director of Hepatology Director, Viral Hepatitis Center Transplantation
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationAn Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD
An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015 Matthew McMahon, MD In the United States, 2.2-3.2 million people are infected with the hepatitis C virus (HCV) Half unaware
More informationTreatment of Hepatitis C in Liver Transplant Patients: Interferon OUT, Direct Antiviral Combos IN
Treatment of Hepatitis C in Liver Transplant Patients: Interferon OUT, Direct Antiviral Combos IN Jennifer C. Price 1 and Norah A. Terrault 1 1 Department of Medicine, University of California San Francisco,
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More information17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in
Management of hepatitis C in special patient groups Minisymposium Challenges in viral hepatitis 14 Lausanne 16.1.14 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB- and Transplant-Center University
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationManagement of HIV/HCV Co-infected Patients
Management of HIV/HCV Co-infected Patients David Wyles, MD Associate Professor of Medicine Division of Infectious Diseases University of California, San Diego San Diego, California Disclosures Grants/Research
More informationTreatment of Chronic Hepatitis C - September 2015 Update
Treatment of Chronic Hepatitis C - September 2015 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Beat Müllhaupt, Andri Rauch, Jan Fehr and Darius
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationRequest for Prior Authorization HEPATITIS C TREATMENTS
IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationTreatment Options for Hepatitis C in the Post Transplant Patient
Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut
More informationNew modalities in the treatment of HCV in pre and post - transplantation setting
New modalities in the treatment of HCV in pre and post - transplantation setting Filiz Araz 1, Christine M. Durand 2, Ahmet Gürakar 3 1 Department of Gastroenterology and Hepatology, Johns Hopkins University
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More informationHepatitis C in 2015. Primary Care Providers: Linkage to Care
Hepatitis C in 2015 Primary Care Providers: Linkage to Care Michael D Voigt Medical Director, Liver Failure and Transplantation University of Iowa, Hospitals and Clinics Disclosures I have NO disclosures
More informationFederal Government Standing Committee on Health
Federal Government Standing Committee on Health Inquiry into Hepatitis C in Australia Professor Gregory Dore Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia Infectious
More informationManagement of non response or relapse following HCV therapy. Greg Dore Darrell Crawford
Management of non response or relapse following HCV therapy Greg Dore Darrell Crawford Learning objectives To understand importance of characterisation of prior HCV therapy response To explore options
More informationCADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report
CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report Product Line: Therapeutic Review Version: 1.0 Volume Number: 3 Issue Number: 1d Publication Date: November 2015
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationDaclatasvir for treating chronic hepatitis C
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Appraisal consultation document Daclatasvir for treating chronic hepatitis C The Department of Health has asked the National Institute for Health and Care
More informationCurrent Antiviral Treatment of HCV cirrhosis
Current Antiviral Treatment of HCV cirrhosis Hugo R. Rosen, M.D. Waterman Endowed Chair in Liver Research Division Head, Gastroenterology & Hepatology Professor of Medicine and Immunology University of
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationIn this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5.
BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection An overall SVR 24 rate of 84.7 percent was
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationThe Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection
The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection A Technology Assessment Final Report April 15, 2014 Completed by: Institute
More informationManaging Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study
Managing Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study Case Prepared by Sinēad Sheils CNC Royal Prince Alfred Hospital, Sydney Friday 17 th May 2013 Nigel 63 yrs old caucasian male HCV
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationObjectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening
Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to
More informationRECOMMENDATIONS FOR THE TREATMENT OF HEPATITIS C
PRZEGL EPIDEMIOL 2015; 69: 515-521 Recommendations Polish Group of HCV Experts: Waldemar Halota, Robert Flisiak, Anna Boroń-Kaczmarska, Jacek Juszczyk, Małgorzata Pawłowska, Krzysztof Simon, Krzysztof
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationThe Use of Protease Inhibitors for the Treatment of Hepatitis C in Liver Transplant Recipients: Is a Bird in the Hand Worth Two in the Bush?
The Use of Protease Inhibitors for the Treatment of Hepatitis C in Liver Transplant Recipients: Is a Bird in the Hand Worth Two in the Bush? Christina Guerra, PharmD PGY-1 Pharmacy Resident University
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationBack to main HCV Drug Development Section. December 2012. By Tracy Swan
Submitted by tracyswan on Wed, 12/12/2012-20:09 Back to main HCV Drug Development Section December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to
More informationCurrent & New Hepatitis C Meds on the Horizon
Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated
More informationPublic Health Plan for the Pharmaceutical Treatment of Hepatitis C
Public Health Plan for the Pharmaceutical Treatment of Hepatitis C December 2014 Contents 1. Introduction...2 2. The Scale of the Problem..4 2.1 Epidemiology of hepatitis C...4 2.2 Burden of disease.....7
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationHepatitis C Infection In Singapore
Hepatitis C Infection In Singapore Richard Guan MBBS, MRCP(UK), FAMS(Gastro), FRCP(Edin), FRCP(Lond) Gastroenterologist & Hepatologist, Mt Elizabeth Medical Centre, Singapore Summary of HCV treatment practice
More informationUnderstanding the Reimbursement Environment in Hepatitis C
Understanding the Reimbursement Environment in Hepatitis C Camilla S. Graham, MD, MPH, Division of Infectious Diseases, Beth Israel Deaconess Medical Center Robert Greenwald, JD, Clinical Professor of
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationHepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
More informationLedipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Massachusetts Medical Society, April 2014 sponsored by Gilead Sciences 23.04.2014 Marie-Luise Lauterjung 1 Zweck der Studie
More informationNo More Special Populations!?
No More Special Populations!? Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and Gastroenterology/Hepatology
More informationHEPATITIS C UPDATE: A Quarter-Century Dramatic Journey. Steve T. Chen M.D. FACP, FACG
HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey Steve T. Chen M.D. FACP, FACG Hepatitis C Virus: Morphology and Characteristics Hepatitis C Virus Discovered in 1989 Nucleic Acid: 9.6 kb ssrna 40-60
More informationProtease inhibitors based triple therapy in patients with advanced fibrosis/cirrhosis
Protease inhibitors based triple therapy in patients with advanced fibrosis/cirrhosis Michael P. Manns Department of Gastroenterology, Hepatology and Endocrinology White Nights of Hepatology, St. Petersburg,
More informationA Proposal for Managing the Harvoni Wave June 22, 2015
A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects
More informationA Cure is Within Reach:
A Cure is Within Reach: A Review of the New HCV Medications Misty Miller, Pharm.D., BCPS, AAHIVP Clinical Assistant Professor University of Oklahoma College of Pharmacy September 11, 2015 Pre Assessment
More informationPreamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of
More informationHIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
More informationManagement of HCV/HIV co-infection in the era of DAA-based therapy
Management of HCV/HIV co-infection in the era of DAA-based therapy Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn Germany Conflict of interest I have received honoraria
More informationRhinivirus - Cancer Treatment
16 th Annual Conference of the National HIV Nurses Association (NHIVNA) Susan Kidger North Manchester General Hospital 26-27 June 2014- City Hall, Cardiff 2 nd Generation Treatment for Hepatitis C and
More informationA New Era in Hepatitis C Therapy: A Public Health Problem with Solutions
A New Era in Hepatitis C Therapy: A Public Health Problem with Solutions Hemant Shah MD MScCH HPTE Clinic and Education Director Francis Family Liver Clinic @ TWH University of Toronto Disclosures Consulting
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationAPASL consensus statements and recommendation on treatment of hepatitis C
DOI 10.1007/s12072-016-9717-6 GUIDELINES APASL consensus statements and recommendation on treatment of hepatitis C Masao Omata 1,2 Tatsuo Kanda 3 Lai Wei 4 Ming-Lung Yu 5 Wang-Long Chuang 6 Alaaeldin Ibrahim
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365
Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2015. All rights reserved.
More information